ReviewFrontiers in immunology
Impact of Diabetes in Patients Diagnosed With COVID-19.
Review in Frontiers in immunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 3 syntheses or guidelines pooled it, 118 citations in OpenAlex.
- Type 2 diabetes mellitus as a predictor of severe outcomes in COVID-19 - a systematic review and meta-analyses.BMC infectious diseases · 2025Pooled it
- Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: A systematic review.Frontiers in immunology · 2022Pooled it
- Insulin Treatment May Increase Adverse Outcomes in Patients With COVID-19 and Diabetes: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2021Pooled it
- Review
- Factors affecting COVID-19 outcomes in Ireland: findings from a national database of 1,408,249 cases diagnosed between 2020 and 2022.BMC public health · 2025Article
- Early Use of Liraglutide for the Treatment of Acute COVID-19 Infection: An Open-Label Single-Center Phase II Safety Study with Biomarker Profiling.Infectious disease reports · 2025Article
- Assessment of serum biomarker changes following the COVID-19 pandemic and vaccination: a cohort study in Sylhet, Bangladesh.Frontiers in public health · 2025Article
- Metabolic reprogramming in viral infections: the interplay of glucose metabolism and immune responses.Frontiers in immunology · 2025Review
- Aberrant innate immune profile associated with COVID-19 mortality in Pretoria, South Africa.Clinical immunology (Orlando, Fla.) · 2024Article
- SARS-CoV-2 Infection Positively Correlates with Hyperglycemia and Inflammatory Markers in COVID-19 Patients: A Clinical Research Study.Diseases (Basel, Switzerland) · 2024Article
- Transient Hyperglycemia in a Patient With Type 2 Diabetes After COVID-19 Messenger RNA Vaccination: A Case Report.Cureus · 2024Article
- Hospital Mortality and Morbidity in Diabetic Patients with COVID-19: A Retrospective Analysis from the UAE.International journal of environmental research and public health · 2024Article
- Long-Term Persistence of COVID-Induced Hyperglycemia: A Cohort Study.The American journal of tropical medicine and hygiene · 2024Article
- Epigenetic perspectives associated with COVID-19 infection and related cytokine storm: an updated review.Infection · 2023Review
- National and regional trends in the prevalence of type 2 diabetes and associated risk factors among Korean adults, 2009-2021.Scientific reports · 2023Article
- Adipose tissue‑derived extracellular vesicles: Systemic messengers in health and disease (Review).Molecular medicine reports · 2023Review
- Review
- Review
- Hospitalized COVID-19 patients with diabetes have an increased risk for pneumonia, intensive care unit requirement, intubation, and death: A cross-sectional cohort study in Mexico in 2020.Health science reports · 2023Article
- Susceptibility of Diabetic Patients to COVID-19 Infections: Clinico-Hematological and Complications Analysis.Vaccines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is a disease caused by the coronavirus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2), known as a highly contagious disease, currently affecting more than 200 countries worldwide. The main feature of SARS-CoV-2 that distinguishes it from other viruses is the speed of transmission combined with higher risk of mortality from acute respiratory distress syndrome (ARDS). People with diabetes mellitus (DM), severe obesity, cardiovascular disease, and hypertension are more likely to get infected and are at a higher risk of mortality from COVID-19. Among elderly patients who are at higher risk of death from COVID-19, 26.8% have DM. Although the reasons for this increased risk are yet to be determined, several factors may contribute to type-2 DM patients' increased susceptibility to infections. A possible factor that may play a role in increasing the risk in people affected by diabetes and/or obesity is the impaired innate and adaptive immune response, characterized by a state of chronic and low-grade inflammation that can lead to abrupt systemic metabolic alteration. SARS patients previously diagnosed with diabetes or hyperglycemia had higher mortality and morbidity rates when compared with patients who were under metabolic control. Similarly, obese individuals are at higher risk of developing complications from SARS-CoV-2. In this review, we will explore the current and evolving insights pertinent to the metabolic impact of coronavirus infections with special attention to the main pathways and mechanisms that are linked to the pathophysiology and treatment of diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.